Loading…
Loading…
HCM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HCM and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HCM and 80,000+ other tickers.
See exactly how HCM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HCM and 80,000+ other tickers.
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic…
Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an early ATTC pipeline. Their Fruzaqla international rollout and improving China execution could also help increase their recurring revenues. Similarly, Sovleplenib, Fanregratinib, and SAFFRON give HCM several options to further derisk its broader pipeline.
[url="]The Hackett Group, Inc.[/url] (NASDAQ: HCKT), an ROI-led AI transformation firm, today released new research examining how artificial intelligence (AI)
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
AI-driven hiring and HR automation are reshaping HCM software, with three companies, namely, PAYC, PCTY and FA standing out for short-term upside.